<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Options Infect DisCurr Treat Options Infect DisCurrent Treatment Options in" exact="Infectious" post="Diseases1523-38201534-6250Springer USNew York pmcid: 7351566232 doi: 10.1007/s40506-020-00232-7 : Viral"/>
 <result pre="in Infectious Diseases1523-38201534-6250Springer USNew York pmcid: 7351566232 doi: 10.1007/s40506-020-00232-7 :" exact="Viral" post="Infections (N Malavige, Section Editor) Vaccination and Therapeutics: Responding"/>
 <result pre="Infectious Diseases1523-38201534-6250Springer USNew York pmcid: 7351566232 doi: 10.1007/s40506-020-00232-7 : Viral" exact="Infections" post="(N Malavige, Section Editor) Vaccination and Therapeutics: Responding to"/>
 <result pre="Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow" exact="Fever" post="BifaniAmanda MakhaMSc1OngEugenia Z.PhD12de AlwisRuklanthiMPH, PhDrukie.dealwis@duke-nus.edu.sg12[1], grid.428397.30000 0004 0385 0924Program"/>
 <result pre="MakhaMSc1OngEugenia Z.PhD12de AlwisRuklanthiMPH, PhDrukie.dealwis@duke-nus.edu.sg12[1], grid.428397.30000 0004 0385 0924Program in Emerging" exact="Infectious" post="Diseases, Duke-NUS Medical School, [2], grid.428397.30000 0004 0385 0924Viral"/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="Purpose of Review At the turn of the nineteenth century," exact="yellow fever" post="(YF) was considered the most dangerous infectious disease with"/>
 <result pre="nineteenth century, yellow fever (YF) was considered the most dangerous" exact="infectious disease" post="with high case fatality. Subsequent, mass vaccination campaigns coupled"/>
 <result pre="century, yellow fever (YF) was considered the most dangerous infectious" exact="disease" post="with high case fatality. Subsequent, mass vaccination campaigns coupled"/>
 <result pre="of a rapidly changing epidemiology and the potential re-emergence of" exact="yellow fever" post="virus (YFV). Furthermore, the first-ever importation of YFV into"/>
 <result pre="vaccination as tools to help eliminate future YFV outbreaks. Keywords" exact="Yellow fever" post="Epidemiology Vaccination Therapeutics Immunity Outbreak control Introduction Yellow fever"/>
 <result pre="Keywords Yellow fever Epidemiology Vaccination Therapeutics Immunity Outbreak control Introduction" exact="Yellow fever" post="(YF) is a re-emerging acute viral disease that less"/>
 <result pre="Immunity Outbreak control Introduction Yellow fever (YF) is a re-emerging" exact="acute" post="viral disease that less than a century ago was"/>
 <result pre="Outbreak control Introduction Yellow fever (YF) is a re-emerging acute" exact="viral" post="disease that less than a century ago was considered"/>
 <result pre="control Introduction Yellow fever (YF) is a re-emerging acute viral" exact="disease" post="that less than a century ago was considered the"/>
 <result pre="less than a century ago was considered the most dangerous" exact="infectious disease" post="in the world [1]. YF is caused by the"/>
 <result pre="than a century ago was considered the most dangerous infectious" exact="disease" post="in the world [1]. YF is caused by the"/>
 <result pre="the world [1]. YF is caused by the etiological agent," exact="yellow fever" post="virus (YFV), which belongs to the flavivirus genus of"/>
 <result pre="present with a wide spectrum of symptoms, ranging from asymptomatic" exact="infections" post="to death, with severe cases displaying high fever, dysfunction"/>
 <result pre="cross-reactivity among co-circulating flaviviruses has meant that confirmed diagnosis is" exact="limited" post="to reference laboratories where viral RNA can be detected"/>
 <result pre="meant that confirmed diagnosis is limited to reference laboratories where" exact="viral" post="RNA can be detected using reverse transcription (RT)-PCR [8â€¢,"/>
 <result pre="[8â€¢, 9]. Therefore, quantifying the true global burden of YF" exact="disease" post="and infections has been challenging. The complex transmission pattern"/>
 <result pre="Therefore, quantifying the true global burden of YF disease and" exact="infections" post="has been challenging. The complex transmission pattern of YFV"/>
 <result pre="cycle where rare opportunistic forest mosquito-feeding events lead to YFV" exact="infection" post="of humans and spread through the urban human population"/>
 <result pre="Africa observes an additional YFV transmission cycle known as the" exact="intermediate" post="cycle (Fig. 1B), where anthropophilic mosquitoes in the savannah"/>
 <result pre="species in South America are far more susceptible to YFV" exact="infection" post="with high mortality [11, 12]. Fig. 1 Map displaying"/>
 <result pre="and 2 in South America. Phylogenetic studies show that the" exact="African" post="lineages have a common ancestor that then spread to"/>
 <result pre="and further evolved to establish the five genotypes: (1) West" exact="African" post="I, (2) West African II, (3) East and Central"/>
 <result pre="establish the five genotypes: (1) West African I, (2) West" exact="African" post="II, (3) East and Central African, (4) East African,"/>
 <result pre="West African I, (2) West African II, (3) East and" exact="Central" post="African, (4) East African, and (5) Angola [1, 13]."/>
 <result pre="(4) East African, and (5) Angola [1, 13]. The South" exact="American" post="genotypes I and II are thought to have evolved"/>
 <result pre="and II are thought to have evolved from the West" exact="African" post="strains during the time of the slave trade when"/>
 <result pre="Unlike flaviviruses such as dengue virus (DENV), YFV is highly" exact="stable" post="with slow epidemic and evolutionary rates [15, 16]. Due"/>
 <result pre="and colleagues created the earliest versions of the live attenuated" exact="yellow fever" post="vaccine [3, 21]. Subsequently, widespread mass vaccination campaigns and"/>
 <result pre="(GAVI), and 47 YFV endemic countries to create the Yellow" exact="Fever" post="Initiative (YFI) in 2006 [24], an initiative that was"/>
 <result pre="mass YF vaccination campaigns and introduction of the vaccine into" exact="childhood" post="immunization programs in high-risk regions. In an emergency preparedness"/>
 <result pre="West and East Africa, with low or no endemicity in" exact="Central" post="Africa (Fig. 1B). In 2013, highly endemic regions in"/>
 <result pre="poor [22â€¢â€¢]. In South America, case fatality rates from YFV" exact="infections" post="is more than double that in Africa (40â€&quot;60% versus"/>
 <result pre="that had previously had low or no risk of YF" exact="infections" post="and therefore, low vaccination coverage [17]. Phylogenetic tracking of"/>
 <result pre="dissemination event to have occurred in â€œCentral-Westâ€� region in the" exact="Brazilian" post="state of GoiÃ¡s about 2Â years prior to the"/>
 <result pre="route 2 towards the south-east) into peri-urban regions of the" exact="Brazilian" post="megapolis, SÃ£o Paulo and Rio de Janeiro [31]. This"/>
 <result pre="confirmed that the 2016â€&quot;2017 epidemic strain was within the South" exact="American" post="(SA) 1 genotype and that the epidemic resulted from"/>
 <result pre="resulted from direct sylvatic spill over to humans with the" exact="absence of" post="sustained YFV transmission within the urban cycle [19, 32,"/>
 <result pre="vaccine, YF17D remains the single best control measure against YFV" exact="infection" post="and is widely regarded as one of the most"/>
 <result pre="the gold standard when examining correlates of protection against future" exact="infection" post="[44, 45]. Protective titers were originally determined by passive"/>
 <result pre="which is not always feasible in the context of natural" exact="infection" post="or mass vaccination. Consequently, plaque reduction neutralizing titer (PRNT)"/>
 <result pre="slow, tedious, not standardizable, require experienced laboratory staff, and are" exact="limited" post="to Biosafety level-3 containment facilities [48]. Therefore, currently, we"/>
 <result pre="who received the YF vaccine in conjunction with the routine" exact="childhood" post="vaccines for measles-mumps-rubella (MMR) had a lower seroconversion rate"/>
 <result pre="with the routine childhood vaccines for measles-mumps-rubella (MMR) had a" exact="lower" post="seroconversion rate (69%) as compared with children who received"/>
 <result pre="status remains to be elucidated. Fig. 2 Determinants of Yellow" exact="Fever" post="live attenuated vaccine immunity. Schematic diagram illustrating different elements"/>
 <result pre="to 95% may be required for high-risk regions to eliminate" exact="yellow fever" post="outbreaks [66]. These disturbing observations are further evidence of"/>
 <result pre="Asibi in a challenge model [46]. In humans, a tenfold" exact="lower" post="dose of YF17D provoked a similar cytokine profile, viremia,"/>
 <result pre="antibody responses in different age groups and genetic background are" exact="limited" post="[68]. Hence, it is imperative that we continue to"/>
 <result pre="against YFV infections. The role of T cell immunity in" exact="yellow fever" post="vaccination remains unclear. Not surprisingly, YF vaccination induces strong"/>
 <result pre="passive transfer of antibodies was sufficient for protection against wildtype" exact="infection" post="[44, 46]. Therefore, it is likely that although both"/>
 <result pre="both B and T cells play a role in establishing" exact="viral" post="clearance, antibody responses play a more dominant role in"/>
 <result pre="particularly in the elderly (â‰¥â€‰60Â years old) [80â€&quot;82]. Vaccine-associated neurotropic" exact="disease" post="(YFV-AND) causes neurological complications that are typically not fatal."/>
 <result pre="neurological complications that are typically not fatal. However, vaccine-associated viscerotropic" exact="disease" post="(YFV-AVD) results in an infection that resembles natural YF"/>
 <result pre="not fatal. However, vaccine-associated viscerotropic disease (YFV-AVD) results in an" exact="infection" post="that resembles natural YF disease accompanied by a high"/>
 <result pre="disease (YFV-AVD) results in an infection that resembles natural YF" exact="disease" post="accompanied by a high fatality rate. Virus isolated from"/>
 <result pre="under-reporting in endemic countries [47]. Additionally, host genetics [56], egg" exact="allergies" post="(due to the manufacturing process) [80], and an active"/>
 <result pre="and an active immune environment [58] have been linked with" exact="disease" post="outcome and could contribute to the frequency of adverse"/>
 <result pre="mortality associated with YF infections, the threat from wildtype YFV" exact="infections" post="outweighs that from YF vaccine-associated AEs [80]. The EYEâ€™s"/>
 <result pre="vaccine doses in chicken embryos [1], the production capability is" exact="limited" post="and unable to meet increased demands during an outbreak"/>
 <result pre="in YF control? There are no approved therapeutics against YFV" exact="infections" post="and treatment of YF disease is reliant on supportive"/>
 <result pre="no approved therapeutics against YFV infections and treatment of YF" exact="disease" post="is reliant on supportive care to alleviate disease symptoms."/>
 <result pre="of YF disease is reliant on supportive care to alleviate" exact="disease" post="symptoms. Although its initial clinical presentation may be benign,"/>
 <result pre="Although its initial clinical presentation may be benign, 15% of" exact="symptomatic" post="patients can rapidly progress to severe yellow fever that"/>
 <result pre="benign, 15% of symptomatic patients can rapidly progress to severe" exact="yellow fever" post="that requires intensive care support [92]. This includes the"/>
 <result pre="prophylactic use of anticonvulsant drugs to reduce the frequency of" exact="seizures" post="and the use of intravenous proton pump inhibitors to"/>
 <result pre="the use of intravenous proton pump inhibitors to treat gastric" exact="bleeding" post="[93]. While there are licensed YF vaccines, as discussed"/>
 <result pre="control strategy (i.e., as prophylaxis when YF vaccine is in" exact="short" post="supply). Drug repurposing has been adopted as a strategy"/>
 <result pre="Sofosbuvir are both nucleoside analog antivirals originally used to treat" exact="chronic hepatitis C" post="infections, which have emerged as promising antivirals for the"/>
 <result pre="are both nucleoside analog antivirals originally used to treat chronic" exact="hepatitis C" post="infections, which have emerged as promising antivirals for the"/>
 <result pre="development of neutralizing antibodies against YFV that completely protected against" exact="secondary" post="YFV challenge, highlighting that the use of these drugs"/>
 <result pre="currently ongoing (clinicaltrials.gov NCT03891420). Recently, two YFV-infected patients presenting with" exact="acute" post="liver failure were treated off-label with Sofosbuvir for a"/>
 <result pre="ongoing (clinicaltrials.gov NCT03891420). Recently, two YFV-infected patients presenting with acute" exact="liver failure" post="were treated off-label with Sofosbuvir for a week as"/>
 <result pre="hoped that these will contribute to both treatment of YF" exact="disease" post="and the control of YF outbreaks. Conclusion The re-emergence"/>
 <result pre="YF vaccine is highly efficacious, vaccine supply shortfalls due to" exact="limited" post="production suggest that the development of new vaccines and"/>
 <result pre="outbreaks. This article is part of the Topical Collection on" exact="Viral" post="Infections Publisherâ€™s Note Springer Nature remains neutral with regard"/>
 <result pre="This article is part of the Topical Collection on Viral" exact="Infections" post="Publisherâ€™s Note Springer Nature remains neutral with regard to"/>
 <result pre="feverJ Clin Virol20156416017310.1016/j.jcv.2014.08.03025453327 2.StaplesJEMonathTPYellow fever: 100 years of discoveryJAMA.2008300896096210.1001/jama.300.8.96018728272 3.FriersonJGThe" exact="yellow fever" post="vaccine: a historyYale J Biol Med2010832778520589188 4.QuaresmaJAPagliariCMedeirosDBDuarteMIVasconcelosPFImmunity and immune"/>
 <result pre="feverRev Med Virol201323530531810.1002/rmv.175223873723 5.JohanssonMAVasconcelosPFStaplesJEThe whole iceberg: estimating the incidence of" exact="yellow fever" post="virus infection from the number of severe casesTrans R"/>
 <result pre="Virol201323530531810.1002/rmv.175223873723 5.JohanssonMAVasconcelosPFStaplesJEThe whole iceberg: estimating the incidence of yellow fever" exact="virus infection" post="from the number of severe casesTrans R Soc Trop"/>
 <result pre="5.JohanssonMAVasconcelosPFStaplesJEThe whole iceberg: estimating the incidence of yellow fever virus" exact="infection" post="from the number of severe casesTrans R Soc Trop"/>
 <result pre="R Soc Trop Med Hyg2014108848248710.1093/trstmh/tru09224980556 6.ShearerFMLongbottomJBrowneAJPigottDMBradyOJKraemerMUGMarinhoFYactayoSde AraÃºjoVEMda NÃ³bregaAAFullmanNRaySEMosserJFStanawayJDLimSSReinerRCJrMoyesCLHaySIGoldingNExisting and potential" exact="infection" post="risk zones of yellow fever worldwide: a modelling analysisLancet"/>
 <result pre="Hyg2014108848248710.1093/trstmh/tru09224980556 6.ShearerFMLongbottomJBrowneAJPigottDMBradyOJKraemerMUGMarinhoFYactayoSde AraÃºjoVEMda NÃ³bregaAAFullmanNRaySEMosserJFStanawayJDLimSSReinerRCJrMoyesCLHaySIGoldingNExisting and potential infection risk zones of" exact="yellow fever" post="worldwide: a modelling analysisLancet Glob Health201863e270e2e810.1016/S2214-109X(18)30024-X29398634 7.GarskeTVan KerkhoveMDYactayoSRonveauxOLewisRFStaplesJEet al.Yellow"/>
 <result pre="7.GarskeTVan KerkhoveMDYactayoSRonveauxOLewisRFStaplesJEet al.Yellow fever in Africa: estimating the burden of" exact="disease" post="and impact of mass vaccination from outbreak and serological"/>
 <result pre="Med2014115e100163810.1371/journal.pmed.100163824800812 8.DomingoCCharrelRNSchmidt-ChanasitJZellerHReuskenCYellow fever in the diagnostics laboratoryEmerg Microbes Infect20187112910.1038/s41426-018-0128-830002363 9.IngelbeenBWeregemereNANoelHTshapendaGPMossokoMNsioJRonsseAAhuka-MundekeSCohuetSKebelaBIUrban" exact="yellow fever" post="outbreak-Democratic Republic of the Congo, 2016: towards more rapid"/>
 <result pre="10.CarringtonCVAugusteAJEvolutionary and ecological factors underlying the tempo and distribution of" exact="yellow fever" post="virus activityInfect Genet Evol20131319821010.1016/j.meegid.2012.08.01522981999 11.FernandesNCunhaMSGuerraJMRessioRACirqueiraCDSIgleziasSDet al.Outbreak of yellow fever"/>
 <result pre="of yellow fever virus activityInfect Genet Evol20131319821010.1016/j.meegid.2012.08.01522981999 11.FernandesNCunhaMSGuerraJMRessioRACirqueiraCDSIgleziasSDet al.Outbreak of" exact="yellow fever" post="among nonhuman primates, Espirito Santo, Brazil, 2017Emerg Infect Dis201723122038204110.3201/eid2312.17068529148378"/>
 <result pre="Santo, Brazil, 2017Emerg Infect Dis201723122038204110.3201/eid2312.17068529148378 12.SilvaNIOSacchettoLde RezendeIMTrindadeGSLaBeaudADde ThoisyBet al.Recent sylvatic" exact="yellow fever" post="virus transmission in Brazil: the news from an old"/>
 <result pre="from an old diseaseVirol J2020171910.1186/s12985-019-1277-731973727 13.MutebiJPWangHLiLBryantJEBarrettADPhylogenetic and evolutionary relationships among" exact="yellow fever" post="virus isolates in AfricaJ Virol200175156999700810.1128/JVI.75.15.6999-7008.200111435580 14.BryantJEHolmesECBarrettADOut of Africa: a"/>
 <result pre="14.BryantJEHolmesECBarrettADOut of Africa: a molecular perspective on the introduction of" exact="yellow fever" post="virus into the AmericasPLoS Pathog200735e7510.1371/journal.ppat.003007517511518 15.ChenCJiangDNiMLiJChenZLiuJYeHWongGLiWZhangYWangBBiYChenDZhangPZhaoXKongYShiWduPXiaoGMaJGaoGFCuiJZhangFLiuWBoXLiAZengHLiuDPhylogenomic analysis unravels evolution"/>
 <result pre="virus into the AmericasPLoS Pathog200735e7510.1371/journal.ppat.003007517511518 15.ChenCJiangDNiMLiJChenZLiuJYeHWongGLiWZhangYWangBBiYChenDZhangPZhaoXKongYShiWduPXiaoGMaJGaoGFCuiJZhangFLiuWBoXLiAZengHLiuDPhylogenomic analysis unravels evolution of" exact="yellow fever" post="virus within hostsPLoS Negl Trop Dis2018129e000673810.1371/journal.pntd.000673830188905 16.KumDBMishraNVranckenBThibautHJWilder-SmithALemeyPNeytsJDallmeierKLimited evolution of"/>
 <result pre="virus within hostsPLoS Negl Trop Dis2018129e000673810.1371/journal.pntd.000673830188905 16.KumDBMishraNVranckenBThibautHJWilder-SmithALemeyPNeytsJDallmeierKLimited evolution of the" exact="yellow fever" post="virus 17d in a mouse infection modelEmerg Microbes Infect2019811734174610.1080/22221751.2019.169439431797751"/>
 <result pre="evolution of the yellow fever virus 17d in a mouse" exact="infection" post="modelEmerg Microbes Infect2019811734174610.1080/22221751.2019.169439431797751 17.FigueiredoPOSilvaATSOliveiraJSMarinhoPERochaFTDomingosGPPobletePCPOliveiraLBSDuarteDCBonjardimCAAbrahÃ£oJSKroonEGDrumondBPOliveiraDBTrindadeGSDetection and molecular characterization of yellow"/>
 <result pre="mouse infection modelEmerg Microbes Infect2019811734174610.1080/22221751.2019.169439431797751 17.FigueiredoPOSilvaATSOliveiraJSMarinhoPERochaFTDomingosGPPobletePCPOliveiraLBSDuarteDCBonjardimCAAbrahÃ£oJSKroonEGDrumondBPOliveiraDBTrindadeGSDetection and molecular characterization of" exact="yellow fever" post="virus, 2017Brazil Ecohealth201815486487010.1007/s10393-018-1364-z30117000 18.RezendeIMSacchettoLMunhoz de MelloEAlvesPAIaniFCMAdelinoTERet al.Persistence of Yellow"/>
 <result pre="yellow fever virus, 2017Brazil Ecohealth201815486487010.1007/s10393-018-1364-z30117000 18.RezendeIMSacchettoLMunhoz de MelloEAlvesPAIaniFCMAdelinoTERet al.Persistence of" exact="Yellow fever" post="virus outside the Amazon Basin, causing epidemics in Southeast"/>
 <result pre="Nobel Prize for a virus vaccineJ Exp Med2007204122779278410.1084/jem.2007229018039952 22.ShearerFMMoyesCLPigottDMBradyOJMarinhoFDeshpandeAet al.Global" exact="yellow fever" post="vaccination coverage from 1970 to 2016: an adjusted retrospective"/>
 <result pre="an adjusted retrospective analysisLancet Infect Dis201717111209121710.1016/S1473-3099(17)30419-X28822780 23.RogersDJWilsonAJHaySIGrahamAJThe global distribution of" exact="yellow fever" post="and dengueAdv Parasitol20066218122010.1016/S0065-308X(05)62006-416647971 24.WHO. Yellow fever initiative providing an"/>
 <result pre="23.RogersDJWilsonAJHaySIGrahamAJThe global distribution of yellow fever and dengueAdv Parasitol20066218122010.1016/S0065-308X(05)62006-416647971 24.WHO." exact="Yellow fever" post="initiative providing an opportunity of a lifetime. In: Organization"/>
 <result pre="Geneva 2010. 25.WHO. International coordination group on vaccine provision for" exact="yellow fever." post="In: Organization WH, editor. Geneva 2019. 26.HamletAJeanKPereaWYactayoSBieyJVan KerkhoveMet al.The"/>
 <result pre="26.HamletAJeanKPereaWYactayoSBieyJVan KerkhoveMet al.The seasonal influence of climate and environment on" exact="yellow fever" post="transmission across AfricaPLoS Negl Trop Dis2018123e000628410.1371/journal.pntd.000628429543798 27.KraemerMUGFariaNRReinerRCJrGoldingNNikolayBStasseSJohanssonMASaljeHFayeOWintGRWNiedrigMShearerFMHillSCThompsonRNBisanzioDTaveiraNNaxHHPradelskiBSRNsoesieEOMurphyNRBogochIIKhanKBrownsteinJSTatemAJde OliveiraTSmithDLSallAAPybusOGHaySICauchemezSSpread of"/>
 <result pre="fever transmission across AfricaPLoS Negl Trop Dis2018123e000628410.1371/journal.pntd.000628429543798 27.KraemerMUGFariaNRReinerRCJrGoldingNNikolayBStasseSJohanssonMASaljeHFayeOWintGRWNiedrigMShearerFMHillSCThompsonRNBisanzioDTaveiraNNaxHHPradelskiBSRNsoesieEOMurphyNRBogochIIKhanKBrownsteinJSTatemAJde OliveiraTSmithDLSallAAPybusOGHaySICauchemezSSpread of" exact="yellow fever" post="virus outbreak in Angola and the Democratic Republic of"/>
 <result pre="Congo 2015-16: a modelling studyLancet Infect Dis201717333033810.1016/S1473-3099(16)30513-828017559 28.ZhaoSStoneLGaoDHeDModelling the large-scale" exact="yellow fever" post="outbreak in Luanda, Angola, and the impact of vaccinationPLoS"/>
 <result pre="doses - June 2017, addendum to vaccines and vaccination against" exact="yellow fever" post="WHO: position paper - June 2013Vaccine.201735435751575210.1016/j.vaccine.2017.06.08728689653 30.â€¢â€¢ WHO. Eliminate"/>
 <result pre="fever WHO: position paper - June 2013Vaccine.201735435751575210.1016/j.vaccine.2017.06.08728689653 30.â€¢â€¢ WHO. Eliminate" exact="Yellow fever" post="Epidemics (EYE): a global strategy, 2017â€&quot;2026. In: Organization WH,"/>
 <result pre="SantosAACFerreira-de-BritoAet al.Distinct YFV lineages co-circulated in the central-western and southeastern" exact="Brazilian" post="regions from 2015 to 2018Front Microbiol201910107910.3389/fmicb.2019.0107931178835 32.FariaNRKraemerMUGHillSCde Jesus GoesJAguiarRSIaniFCMet"/>
 <result pre="2018Front Microbiol201910107910.3389/fmicb.2019.0107931178835 32.FariaNRKraemerMUGHillSCde Jesus GoesJAguiarRSIaniFCMet al.Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potentialScience.2018361640589489910.1126/science.aat711530139911 33.CunhaMDPDuarte-NetoANPourSZOrtiz-BaezASCernyJPereiraBBSet al.Origin of the Sao Paulo"/>
 <result pre="fever virus transmission potentialScience.2018361640589489910.1126/science.aat711530139911 33.CunhaMDPDuarte-NetoANPourSZOrtiz-BaezASCernyJPereiraBBSet al.Origin of the Sao Paulo" exact="yellow fever" post="epidemic of 2017-2018 revealed through molecular epidemiological analysis of"/>
 <result pre="34.PossasCLourenco-de-OliveiraRTauilPLPinheiroFPPissinattiACunhaRVDet al.Yellow fever outbreak in Brazil: the puzzle of rapid" exact="viral" post="spread and challenges for immunisationMem Inst Oswaldo Cruz201811310e18027810.1590/0074-0276018027830427974 35.Couto-LimaDMadecYBersotMICamposSSMottaMASantosFBDet"/>
 <result pre="Cruz201811310e18027810.1590/0074-0276018027830427974 35.Couto-LimaDMadecYBersotMICamposSSMottaMASantosFBDet al.Potential risk of re-emergence of urban transmission of" exact="yellow fever" post="virus in Brazil facilitated by competent Aedes populationsSci Rep201771484810.1038/s41598-017-05186-328687779"/>
 <result pre="Aedes populationsSci Rep201771484810.1038/s41598-017-05186-328687779 36.NavaAShimabukuroJSChmuraAALuzSLBThe impact of global environmental changes on" exact="infectious disease" post="emergence with a focus on risks for BrazilILAR J201758339340010.1093/ilar/ilx03429253158"/>
 <result pre="populationsSci Rep201771484810.1038/s41598-017-05186-328687779 36.NavaAShimabukuroJSChmuraAALuzSLBThe impact of global environmental changes on infectious" exact="disease" post="emergence with a focus on risks for BrazilILAR J201758339340010.1093/ilar/ilx03429253158"/>
 <result pre="42.SongRGuanSLeeSSChenZChenCHanLet al.Late or lack of vaccination linked to importation of" exact="yellow fever" post="from Angola to ChinaEmerg Infect Dis20182471383138610.3201/eid2407.171868 43.Wilder-SmithALeongWYImportation of yellow"/>
 <result pre="yellow fever from Angola to ChinaEmerg Infect Dis20182471383138610.3201/eid2407.171868 43.Wilder-SmithALeongWYImportation of" exact="yellow fever" post="into China: assessing travel patternsJ Travel Med2017244tax00810.1093/jtm/tax008 44.JulanderJGTrentDWMonathTPImmune correlates"/>
 <result pre="assessing travel patternsJ Travel Med2017244tax00810.1093/jtm/tax008 44.JulanderJGTrentDWMonathTPImmune correlates of protection against" exact="yellow fever" post="determined by passive immunization and challenge in the hamster"/>
 <result pre="47.AmannaIJSlifkaMKQuestions regarding the safety and duration of immunity following live" exact="yellow fever" post="vaccinationExpert Rev Vaccines201615121519153310.1080/14760584.2016.119825927267203 48.JonkerEFVisserLGRoukensAHAdvances and controversies in yellow fever"/>
 <result pre="live yellow fever vaccinationExpert Rev Vaccines201615121519153310.1080/14760584.2016.119825927267203 48.JonkerEFVisserLGRoukensAHAdvances and controversies in" exact="yellow fever" post="vaccinationTher Adv Vaccines20131414415210.1177/205101361349895424757521 49.HepburnMJKortepeterMGPittmanPRBoudreauEFMangiaficoJABuckPANorrisSLAndersonELNeutralizing antibody response to booster vaccination"/>
 <result pre="Vaccines20131414415210.1177/205101361349895424757521 49.HepburnMJKortepeterMGPittmanPRBoudreauEFMangiaficoJABuckPANorrisSLAndersonELNeutralizing antibody response to booster vaccination with the 17d" exact="yellow fever" post="vaccineVaccine.200624152843284910.1016/j.vaccine.2005.12.05516494976 50.JeanKDonnellyCAFergusonNMGarskeTA meta-analysis of serological response associated with yellow"/>
 <result pre="yellow fever vaccineVaccine.200624152843284910.1016/j.vaccine.2005.12.05516494976 50.JeanKDonnellyCAFergusonNMGarskeTA meta-analysis of serological response associated with" exact="yellow fever" post="vaccinationAm J Trop Med Hyg20169561435143910.4269/ajtmh.16-040127928091 51.MonathTPNicholsRArchambaultWTMooreLMarchesaniRTianJet al.Comparative safety and"/>
 <result pre="Trop Med Hyg20169561435143910.4269/ajtmh.16-040127928091 51.MonathTPNicholsRArchambaultWTMooreLMarchesaniRTianJet al.Comparative safety and immunogenicity of two" exact="yellow fever" post="17D vaccines (ARILVAX and YF-VAX) in a phase III"/>
 <result pre="clinical trialAm J Trop Med Hyg2002665810.4269/ajtmh.2002.66.533 52.DomingoCFraissinetJAnsahPOKellyCBhatNSowSOet al.Long-term immunity against" exact="yellow fever" post="in children vaccinated during infancy: a longitudinal cohort studyLancet"/>
 <result pre="SilvaFMda Luz Fernandes LealMde AguiarSGDo NascimentoJPIguchiTet al.Immunogenicity of WHO-17D and" exact="Brazilian" post="17DD yellow fever vaccines- a randomized trialRev Saude Publica2004385810.1590/S0034-89102004000500009"/>
 <result pre="Fernandes LealMde AguiarSGDo NascimentoJPIguchiTet al.Immunogenicity of WHO-17D and Brazilian 17DD" exact="yellow fever" post="vaccines- a randomized trialRev Saude Publica2004385810.1590/S0034-89102004000500009 54.de NoronhaTGde Lourdes"/>
 <result pre="LemosJAMaria Barbosa de LimaSMartins-FilhoOAet al.Duration of post-vaccination humoral immunity against" exact="yellow fever" post="in childrenVaccine.201937487147715410.1016/j.vaccine.2019.09.05131590934 55.Campi-AzevedoACReisLRPeruhype-MagalhaesVCoelho-Dos-ReisJGAntonelliLRFonsecaCTet al.Short-lived immunity after 17DD yellow fever"/>
 <result pre="against yellow fever in childrenVaccine.201937487147715410.1016/j.vaccine.2019.09.05131590934 55.Campi-AzevedoACReisLRPeruhype-MagalhaesVCoelho-Dos-ReisJGAntonelliLRFonsecaCTet al.Short-lived immunity after 17DD" exact="yellow fever" post="single dose indicates that booster vaccination may be required"/>
 <result pre="childrenFront Immunol201910219210.3389/fimmu.2019.0219231616412 56.Blake LE, Garcia-Blanco MA. Human genetic variation and" exact="yellow fever" post="mortality during 19th century U.S. epidemics. MBio. 2014;5(3). 10.1128/mBio.01253-14"/>
 <result pre="century U.S. epidemics. MBio. 2014;5(3). 10.1128/mBio.01253-14 57.TeoTHLumFMGhaffarKChanYHAmrunSNTanJJLLeeCYPChuaTKCarissimoGLeeWWLClaserCRajarethinamRRÃ©niaLNgLFPPlasmodium co-infection protects against" exact="chikungunya" post="virus-induced pathologiesNat Commun201891390510.1038/s41467-018-06227-930254309 58.MuyanjaESsemagandaANgauvPCubasRPerrinHSrinivasanDCanderanGLawsonBKopycinskiJGrahamASRoweDKSmithMJIsernSMichaelSSilvestriGVanderfordTHCastroEPantaleoGSingerJGillmourJKiwanukaNNanvubyaASchmidtCBirungiJCoxJHaddadEKKaleebuPFastPSekalyRPTrautmannLGaucherDImmune activation alters cellular and humoral"/>
 <result pre="pathologiesNat Commun201891390510.1038/s41467-018-06227-930254309 58.MuyanjaESsemagandaANgauvPCubasRPerrinHSrinivasanDCanderanGLawsonBKopycinskiJGrahamASRoweDKSmithMJIsernSMichaelSSilvestriGVanderfordTHCastroEPantaleoGSingerJGillmourJKiwanukaNNanvubyaASchmidtCBirungiJCoxJHaddadEKKaleebuPFastPSekalyRPTrautmannLGaucherDImmune activation alters cellular and humoral responses to" exact="yellow fever" post="17D vaccineJ Clin Invest201412473147315810.1172/JCI7542924911151 59.Campi-AzevedoACCosta-PereiraCAntonelliLRFonsecaCTTeixeira-CarvalhoAVillela-RezendeGSantosRABatistaMACamposFMPacheco-PortoLMelo JÃºniorOAHossellDMSHCoelho-dos-ReisJGPeruhype-MagalhÃ£esVCosta-SilvaMFde OliveiraJGFariasRHNoronhaTGLemosJAvon DoellingerVRSimÃµesMde SouzaMMMalaquiasLCPersiHRPereiraJMMartinsJADornelas-RibeiroMVinhasAAAlvesTRMaiaMLFreireMSMartinsRMHommaARomanoAPMDominguesCMTauilPLVasconcelosPFRiosMCaldasIRCamachoLAMartins-FilhoOABooster"/>
 <result pre="DoellingerVRSimÃµesMde SouzaMMMalaquiasLCPersiHRPereiraJMMartinsJADornelas-RibeiroMVinhasAAAlvesTRMaiaMLFreireMSMartinsRMHommaARomanoAPMDominguesCMTauilPLVasconcelosPFRiosMCaldasIRCamachoLAMartins-FilhoOABooster dose after 10 years is recommended following 17DD-YF" exact="primary" post="vaccinationHum Vaccin Immunother201612249150210.1080/21645515.2015.108269326360663 60.GotuzzoEYactayoSCordovaEEfficacy and duration of immunity after"/>
 <result pre="primary vaccinationHum Vaccin Immunother201612249150210.1080/21645515.2015.108269326360663 60.GotuzzoEYactayoSCordovaEEfficacy and duration of immunity after" exact="yellow fever" post="vaccination: systematic review on the need for a booster"/>
 <result pre="61.PolandJDCalisherCHMonathTPDownsWGMurphyKPersistence of neutralizing antibody 30â€&quot;35 years after immunization with 17D" exact="yellow fever" post="vaccineBull World Health Organ19815965 62.WietenRWJonkerEFFvan LeeuwenEMMRemmerswaalEBMten BergeIJMde VisserAWvan GenderenPJJGoorhuisAVisserLGGrobuschMPde"/>
 <result pre="Health Organ19815965 62.WietenRWJonkerEFFvan LeeuwenEMMRemmerswaalEBMten BergeIJMde VisserAWvan GenderenPJJGoorhuisAVisserLGGrobuschMPde BreeGJA single 17D" exact="yellow fever" post="vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody"/>
 <result pre="63.The World Health Organization. Lifetime validity of one dose of" exact="yellow fever" post="vaccine: amendment to annex 7 of IHR (2005). International"/>
 <result pre="Amanna IJ, et al. Persistence of neutralizing antibody responses among" exact="yellow fever" post="virus 17D Vaccinees living in a nonendemic setting. J"/>
 <result pre="Infect Dis. 2019. 10.1093/infdis/jiz374. 65.collab: Collaborative group for studies on" exact="yellow fever" post="vDuration of post-vaccination immunity against yellow fever in adultsVaccine.201432394977498410.1016/j.vaccine.2014.07.02125090646"/>
 <result pre="for studies on yellow fever vDuration of post-vaccination immunity against" exact="yellow fever" post="in adultsVaccine.201432394977498410.1016/j.vaccine.2014.07.02125090646 66.Ndeffo-Mbah ML, Pandey A. Global risk and"/>
 <result pre="adultsVaccine.201432394977498410.1016/j.vaccine.2014.07.02125090646 66.Ndeffo-Mbah ML, Pandey A. Global risk and elimination of" exact="yellow fever" post="epidemics. J Infect Dis. 2019. 10.1093/infdis/jiz375. 67.PatelDSimonsHYellow fever vaccination:"/>
 <result pre="vaccination: is one dose always enough?Travel Med Infect Dis201311526627310.1016/j.tmaid.2013.08.00724074827 68.VanniceKWilder-SmithAHombachJFractional-dose" exact="yellow fever" post="vaccination - advancing the evidence baseN Engl J Med2018379760360510.1056/NEJMp180343329995585"/>
 <result pre="evidence baseN Engl J Med2018379760360510.1056/NEJMp180343329995585 69.Campi-AzevedoACde AlmeidaEPCoelho-Dos-ReisJGPeruhype-MagalhaesVVillela-RezendeGQuaresmaPFet al.Subdoses of 17DD" exact="yellow fever" post="vaccine elicit equivalent virological:immunological kinetics timelineBMC Infect Dis20141439110.1186/1471-2334-14-39125022840 70.RoukensAHVossenACBredenbeekPJvan"/>
 <result pre="elicit equivalent virological:immunological kinetics timelineBMC Infect Dis20141439110.1186/1471-2334-14-39125022840 70.RoukensAHVossenACBredenbeekPJvan DisselJTVisserLGIntradermally administered" exact="yellow fever" post="vaccine at reduced dose induces a protective immune response:"/>
 <result pre="controlled non-inferiority trialPLoS One200834e199310.1371/journal.pone.000199318431480 71.CaseyRMHarrisJBAhuka-MundekeSDixonMGKizitoGMNselePMUmutesiGLavenJKosoyOPalukuGGueyeASHydeTBEwetolaRSheriaGKMMuyembe-TamfumJJStaplesJEImmunogenicity of fractional-dose vaccine during a" exact="yellow fever" post="outbreak - final reportN Engl J Med2019381544445410.1056/NEJMoa171043029443626 72.MartinsRMMaia MdeLFariasRHCamachoLAFreireMSGallerRet"/>
 <result pre="outbreak - final reportN Engl J Med2019381544445410.1056/NEJMoa171043029443626 72.MartinsRMMaia MdeLFariasRHCamachoLAFreireMSGallerRet al.17DD" exact="yellow fever" post="vaccine: a double blind, randomized clinical trial of immunogenicity"/>
 <result pre="dose-response studyHum Vaccin Immunother20139487988810.4161/hv.2298223364472 73.RoukensAHEvan HalemKde VisserAWVisserLGLong-term protection after fractional-dose" exact="yellow fever" post="vaccination: follow-up study of a randomized, controlledNoninferiority Trial Ann"/>
 <result pre="Med20181691176176510.7326/M18-152930476963 74.de MenezesMRMaiaMLSde LimaSMBde NoronhaTGXavierJRCamachoLABet al.Duration of post-vaccination immunity to" exact="yellow fever" post="in volunteers eight years after a dose-response studyVaccine.201836284112411710.1016/j.vaccine.2018.05.04129784469 75.GaucherDTherrienRKettafNAngermannBRBoucherGFilali-MouhimAet"/>
 <result pre="MostRGAkondyRSGlidewellJTAlbottSMasopustDMurali-KrishnaKMaharPLEdupugantiSLalorSGermonSdel RioCMulliganMJStapransSIAltmanJDFeinbergMBAhmedRHuman effector and memory CD8+ T cell responses to" exact="smallpox" post="and yellow fever vaccinesImmunity.200828571072210.1016/j.immuni.2008.02.02018468462 78.VeitONiedrigMChapuis-TaillardCCavassiniMMossdorfESchmidPBaeHGLitzbaNStaubTHatzCFurrerHcollab: the Swiss HIV Cohort"/>
 <result pre="effector and memory CD8+ T cell responses to smallpox and" exact="yellow fever" post="vaccinesImmunity.200828571072210.1016/j.immuni.2008.02.02018468462 78.VeitONiedrigMChapuis-TaillardCCavassiniMMossdorfESchmidPBaeHGLitzbaNStaubTHatzCFurrerHcollab: the Swiss HIV Cohort StudyImmunogenicity and safety"/>
 <result pre="vaccinesImmunity.200828571072210.1016/j.immuni.2008.02.02018468462 78.VeitONiedrigMChapuis-TaillardCCavassiniMMossdorfESchmidPBaeHGLitzbaNStaubTHatzCFurrerHcollab: the Swiss HIV Cohort StudyImmunogenicity and safety of" exact="yellow fever" post="vaccination for 102 HIV-infected patientsClin Infect Dis200948565966610.1086/59700619191654 79.MonathTPMcCarthyKBedfordPJohnsonCTNicholsRYoksanSet al.Clinical"/>
 <result pre="against flavivirus infectionsVaccine.2002201410.1016/S0264-410X(01)00457-1 80.MonathTPReview of the risks and benefits of" exact="yellow fever" post="vaccination including some new analysesExpert Rev Vaccines201211442744810.1586/erv.12.622551029 81.MartinMWeldLTsaiTFMootreyGTChenRTNiuMet al.Advanced"/>
 <result pre="al.Advanced age a risk factor for illness temporally associated with" exact="yellow fever" post="vaccinationEmerg Infect Dis200176710.3201/eid0706.010605 82.KhromavaAYEidexRBWeldLHKohlKSBradshawRDChenRTCetronMScollab: Yellow Fever Vaccine Safety Working"/>
 <result pre="temporally associated with yellow fever vaccinationEmerg Infect Dis200176710.3201/eid0706.010605 82.KhromavaAYEidexRBWeldLHKohlKSBradshawRDChenRTCetronMScollab: Yellow" exact="Fever" post="Vaccine Safety Working GroupYellow fever vaccine: an updated assessment"/>
 <result pre="for serious adverse eventsVaccine.200523253256326310.1016/j.vaccine.2005.01.08915837230 83.GallerRPugachevKVSantosCLOcranSWJaborAVRodriguesSGet al.Phenotypic and molecular analyses of" exact="yellow fever" post="17DD vaccine viruses associated with serious adverse events in"/>
 <result pre="serious adverse events in BrazilVirology.2001290230931910.1006/viro.2001.116811883195 84.VasconcelosPFCLunaEJGallerRSilvaLJCoimbraTLBarrosVLRSMonathTPRodiguesSGLavalCCostaZGVilelaMFGSantosCLSPapaiordanouCMOAlvesVAFAndradeLDSatoHKRosaESTFroguasGBLacavaEAlmeidaLMRCruzACRRoccoIMSantosRTMOlivaOFPYellowBSerious adverse events associated with" exact="yellow fever" post="17DD vaccine in Brazil: a report of two casesLancet20013589276919710.1016/s0140-6736(01)05326-011463409"/>
 <result pre="in Brazil: a report of two casesLancet20013589276919710.1016/s0140-6736(01)05326-011463409 85.SuzanoCEAmaralESatoHKPapaiordanouPMCampinas group on" exact="yellow fever" post="immunization during the effects of yellow fever immunization (17DD)"/>
 <result pre="85.SuzanoCEAmaralESatoHKPapaiordanouPMCampinas group on yellow fever immunization during the effects of" exact="yellow fever" post="immunization (17DD) inadvertently used in early pregnancy during a"/>
 <result pre="deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe" exact="yellow fever" post="virus infection in micePLoS Negl Trop Dis2016102e000446410.1371/journal.pntd.000446426886513 88.MacielMJrCruz FdaSCordeiroMTda"/>
 <result pre="encoding YF-17D antigens induces long-lasting protection from severe yellow fever" exact="virus infection" post="in micePLoS Negl Trop Dis2016102e000446410.1371/journal.pntd.000446426886513 88.MacielMJrCruz FdaSCordeiroMTda MottaMACassemiroKMMaia RdeCet"/>
 <result pre="YF-17D antigens induces long-lasting protection from severe yellow fever virus" exact="infection" post="in micePLoS Negl Trop Dis2016102e000446410.1371/journal.pntd.000446426886513 88.MacielMJrCruz FdaSCordeiroMTda MottaMACassemiroKMMaia RdeCet"/>
 <result pre="Trop Dis2016102e000446410.1371/journal.pntd.000446426886513 88.MacielMJrCruz FdaSCordeiroMTda MottaMACassemiroKMMaia RdeCet al.A DNA vaccine against" exact="yellow fever" post="virus: development and evaluationPLoS Negl Trop Dis201594e000369310.1371/journal.pntd.000369325875109 89.JulanderJGTestoriMCheminayCVolkmannAImmunogenicity and"/>
 <result pre="Trop Dis201594e000369310.1371/journal.pntd.000369325875109 89.JulanderJGTestoriMCheminayCVolkmannAImmunogenicity and protection after vaccination with a modified" exact="vaccinia" post="virus Ankara-vectored yellow fever vaccine in the hamster modelFront"/>
 <result pre="and protection after vaccination with a modified vaccinia virus Ankara-vectored" exact="yellow fever" post="vaccine in the hamster modelFront Immunol20189175610.3389/fimmu.2018.0175630116244 90.TotteySShojiYJonesRMChichesterJAGreenBJMusiychukKet al.Plant-produced subunit"/>
 <result pre="the hamster modelFront Immunol20189175610.3389/fimmu.2018.0175630116244 90.TotteySShojiYJonesRMChichesterJAGreenBJMusiychukKet al.Plant-produced subunit vaccine candidates against" exact="yellow fever" post="induce virus neutralizing antibodies and confer protection against viral"/>
 <result pre="yellow fever induce virus neutralizing antibodies and confer protection against" exact="viral" post="challenge in animal modelsAm J Trop Med Hyg201898242043110.4269/ajtmh.16-029329231157 91.MonathTPLeeCKJulanderJGBrownABeasleyDWWattsDMHaymanEGuertinPMakowieckiJCrowellJLevesquePBowickGCMorinMFowlerETrentDWInactivated"/>
 <result pre="viral challenge in animal modelsAm J Trop Med Hyg201898242043110.4269/ajtmh.16-029329231157 91.MonathTPLeeCKJulanderJGBrownABeasleyDWWattsDMHaymanEGuertinPMakowieckiJCrowellJLevesquePBowickGCMorinMFowlerETrentDWInactivated" exact="yellow fever" post="17D vaccine: development and nonclinical safety, immunogenicity and protective"/>
 <result pre="yellow fever: an observational cohort studyLancet Infect Dis201919775075810.1016/S1473-3099(19)30125-231104909 93.HoYLJoelsonsDLeiteGFCMalbouissonLMSSongATWPerondiBet al.Severe" exact="yellow fever" post="in Brazil: clinical characteristics and managementJ Travel Med2019265taz04010.1093/jtm/taz04031150098 94.MercorelliBPaluGLoregianADrug"/>
 <result pre="Brazil: clinical characteristics and managementJ Travel Med2019265taz04010.1093/jtm/taz04031150098 94.MercorelliBPaluGLoregianADrug repurposing for" exact="viral" post="infectious diseases: how far are we?Trends Microbiol2018261086587610.1016/j.tim.2018.04.00429759926 95.SacramentoCQde MeloGRde"/>
 <result pre="clinical characteristics and managementJ Travel Med2019265taz04010.1093/jtm/taz04031150098 94.MercorelliBPaluGLoregianADrug repurposing for viral" exact="infectious" post="diseases: how far are we?Trends Microbiol2018261086587610.1016/j.tim.2018.04.00429759926 95.SacramentoCQde MeloGRde FreitasCSRochaNHoelzLVMirandaMet"/>
 <result pre="virus replicationSci Rep201771634510.1038/s41598-017-06612-228740124 97.JulanderJGBantiaSTaubenheimBRMinningDMKotianPMorreyJDSmeeDFSheridanWPBabuYSBCX4430, a novel nucleoside analog, effectively treats" exact="yellow fever" post="in a hamster modelAntimicrob Agents Chemother201458116607661410.1128/AAC.03368-1425155605 98.de FreitasCSHigaLMSacramentoCQFerreiraACReisPADelvecchioRMonteiroFLBarbosa-LimaGJames WestgarthHVieiraYRMattosMRochaNHoelzLVBLemeRPPBastosMML."/>
 <result pre="in vivoPLoS Negl Trop Dis2019131e000707210.1371/journal.pntd.000707230699122 99.MendesEAPilgerDRBSantos NastriACSMaltaFMPascoalinoBDSCarneiro D'AlbuquerqueLAet al.Sofosbuvir inhibits" exact="yellow fever" post="virus in vitro and in patients with acute liver"/>
 <result pre="inhibits yellow fever virus in vitro and in patients with" exact="acute" post="liver failureAnn Hepatol201918681682410.1016/j.aohep.2019.09.00131594756 100.Lu X, Xiao H, Li S,"/>
 <result pre="of a human neutralizing and protective monoclonal antibody targeting the" exact="yellow fever" post="virus envelope. Cell Rep. 2019;26(2):438â€&quot;46 e5. 10.1016/j.celrep.2018.12.065."/>
</results>
